• Product NameTofacitinib (CP-690550) Citrate
• Brief DescriptionInhibitors
• Purification99.47%
• Biological ActivityTofacitinib citrate (CP-690550 citrate) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.
• Target NameJAK inhibitor; ROCK inhibitor; Src inhibitor
• CAS No. 540737-29-9
• Calculated MW 504.49
• Formulation C22H28N6O8
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
  Pathways:Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Stem Cells; JAK/STAT signaling
  Receptor:JAK1; JAK2; JAK3; ROCK2; Lck
  Boling pt:
  Melting pt:
  Solubility:DMSO: 100 mg/mL warmed (198.21 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Changelian PS, et al, Science, 2003, 302(5646), 875-878.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting